TScan Therapeutics, Inc. (TCRX) - Dilution Analysis

10-Q filing | 52.5M shares outstanding

10-Q filing | 52.3M shares outstanding

10-K filing | 52.3M shares outstanding

S-3 filing: Tscan Therapeutics files an S-3 to offer up to $300,000,000 in aggregate principal amount of its voting common stock, non-voting common stock, preferred stock, debt securities, warrants and/or units.

8-K filing: TScan Therapeutics, Inc. issued 3,134,796 shares of voting common stock to a lender on November 20, 2024, upon conversion of $15 million of principal amount of a loan at a conversion price of $4.785 per share, pursuant to a conversion notice received on November 15, 2024.

10-Q filing | 49.1M shares outstanding

10-Q filing | 48.7M shares outstanding

10-Q filing | 48.6M shares outstanding

10-K filing | 43.6M shares outstanding

S-3 filing: TSCAN Therapeutics, Inc. may from time to time issue up to $300,000,000 in aggregate principal amount of voting common stock, non-voting common stock, preferred stock, and debt securities.

10-Q filing | 43.5M shares outstanding

10-Q filing | 47.2M shares outstanding

S-3/A filing: This is an S-3/A filing related to a shelf registration statement.

S-3/A filing: This is an S-3/A filing. The filing discusses undertakings related to offers or sales being made and post-effective amendments to the registration statement.

10-Q filing | 19.5M shares outstanding

10-K filing | 19.1M shares outstanding

S-3 filing: This S-3 filing covers the offer and resale of 2,784,792 shares of voting common stock and 4,276,588 shares of non-voting common stock by selling stockholders.

10-Q filing | 18.9M shares outstanding

S-3 filing: Tscan Therapeutics files an S-3 registration statement to offer up to $250,000,000 in voting common stock, preferred stock, debt securities, warrants and/or units.

10-Q filing | 18.9M shares outstanding

10-Q filing | 18.9M shares outstanding

10-K filing | 24.0M shares outstanding

10-Q filing | 18.6M shares outstanding

10-Q filing | 18.8M shares outstanding

S-1/A filing: This S-1/A filing details a proposed offering of common stock, with an option for underwriters to purchase additional shares, and information regarding previous sales of Series B convertible preferred stock to various entities.

S-1/A filing: This is an S-1/A filing for an initial public offering of common stock. It includes details regarding a Series B convertible preferred stock financing, and an option for underwriters to purchase additional shares.

S-1/A filing: This is an S-1/A filing for common stock. Details include ranking, voting rights, dividends, and liquidation procedures for both Voting and Non-Voting Common Stock.

S-1/A filing: S-1/A filing describing Series B Convertible Preferred Stock Financing

S-1 filing: The filing details the issuance and sale of Series B convertible preferred stock in July, August and November 2019.